Charles River Laboratories International, Inc. Share Price
Equities
CRL
US1598641074
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 194.43 USD | -0.22% |
|
+5.29% | +5.33% |
| Capitalization | 956.9Cr 814.13Cr 760.09Cr 713.11Cr 1.32TCr 86TCr 1.44TCr 8.86TCr 3.44TCr 41TCr 3.59TCr 3.51TCr 1,48600Cr | P/E ratio 2025 * |
46.4x | P/E ratio 2026 * | 26.9x |
|---|---|---|---|---|---|
| Enterprise value | 1.15TCr 980.71Cr 915.61Cr 859.02Cr 1.59TCr 1,04000Cr 1.73TCr 11TCr 4.14TCr 49TCr 4.33TCr 4.23TCr 1,79000Cr | EV / Sales 2025 * |
2.88x | EV / Sales 2026 * | 2.74x |
| Free-Float |
97.96% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Charles River Laboratories International, Inc.
| 1 day | -0.22% | ||
| 1 week | +5.29% | ||
| Current month | +9.14% | ||
| 1 month | +15.07% | ||
| 3 months | +26.85% | ||
| 6 months | +28.76% | ||
| Current year | +5.33% |
| 1 week | 182.71 | 196.38 | |
| 1 month | 156.72 | 196.38 | |
| Current year | 91.86 | 199.66 | |
| 1 year | 91.86 | 199.66 | |
| 3 years | 91.86 | 275 | |
| 5 years | 91.86 | 460.21 | |
| 10 years | 65.7 | 460.21 |
| Manager | Title | Age | Since |
|---|---|---|---|
James Foster
CEO | Chief Executive Officer | 74 | 01/01/1992 |
Michael Knell
DFI | Director of Finance/CFO | 48 | 29/09/2025 |
Julie Frearson
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/2014 |
| Director | Title | Age | Since |
|---|---|---|---|
James Foster
CHM | Chairman | 74 | 01/01/2000 |
Martin MacKay
BRD | Director/Board Member | 68 | 05/07/2017 |
Virginia Wilson
BRD | Director/Board Member | 70 | 01/10/2019 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.22% | +5.29% | -1.33% | -7.49% | 958.96Cr | ||
| -2.53% | -5.31% | +0.19% | +14.63% | 4.7TCr | ||
| +1.37% | -0.55% | +11.21% | +8.37% | 3.8TCr | ||
| -0.57% | -5.04% | +71.11% | +62.86% | 3.57TCr | ||
| +0.54% | +1.85% | +11.96% | +17.47% | 2.76TCr | ||
| +0.96% | -1.79% | +65.57% | +175.14% | 1.58TCr | ||
| +0.81% | +1.06% | +66.02% | +230.15% | 1.51TCr | ||
| +2.19% | +1.14% | -12.05% | -2.48% | 1.42TCr | ||
| -1.61% | -1.40% | +64.13% | - | 1.34TCr | ||
| +0.65% | -3.30% | +106.85% | +111.04% | 1.27TCr | ||
| Average | +0.23% | -0.91% | +38.37% | +67.74% | 2.29TCr | |
| Weighted average by Cap. | -0.20% | -1.59% | +32.16% | +52.25% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 400.61Cr 340.84Cr 318.22Cr 298.55Cr 552.03Cr 36TCr 601Cr 3.71TCr 1.44TCr 17TCr 1.5TCr 1.47TCr 62TCr | 407.52Cr 346.71Cr 323.7Cr 303.69Cr 561.54Cr 37TCr 611.35Cr 3.77TCr 1.47TCr 17TCr 1.53TCr 1.5TCr 63TCr |
| Net income | 21Cr 18Cr 17Cr 16Cr 30Cr 1.94TCr 32Cr 198.95Cr 77Cr 916Cr 81Cr 79Cr 3.34TCr | 38Cr 32Cr 30Cr 28Cr 52Cr 3.44TCr 57Cr 352.55Cr 136.99Cr 1.62TCr 142.95Cr 139.93Cr 5.91TCr |
| Net Debt | 195.79Cr 166.58Cr 155.52Cr 145.91Cr 269.79Cr 18TCr 293.72Cr 1.81TCr 704.04Cr 8.34TCr 734.72Cr 719.15Cr 30TCr | 158.92Cr 135.21Cr 126.23Cr 118.43Cr 218.98Cr 14TCr 238.41Cr 1.47TCr 571.46Cr 6.77TCr 596.36Cr 583.72Cr 25TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/25/11 | 194.43 $ | -0.22% | 6,39,012 |
| 10/25/10 | 194.85 $ | +4.76% | 11,07,338 |
| 09/25/09 | 185.99 $ | -0.60% | 10,70,104 |
| 08/25/08 | 187.12 $ | +1.52% | 8,10,819 |
| 05/25/05 | 184.31 $ | +0.15% | 7,05,080 |
Delayed Quote Nyse, December 12, 2025 at 02:30 am IST
More quotesTrader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CRL Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















